1. Home
  2. CDXS vs SENS Comparison

CDXS vs SENS Comparison

Compare CDXS & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.58

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$9.28

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDXS
SENS
Founded
2002
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Industrial Machinery/Components
Sector
Industrials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
256.3M
301.2M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
CDXS
SENS
Price
$1.58
$9.28
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
1.0M
782.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
43.82
N/A
EPS
N/A
N/A
Revenue
$138,590,000.00
$16,389,000.00
Revenue This Year
$7.73
$74.15
Revenue Next Year
$14.24
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
32.30
19.85
52 Week Low
$0.96
$0.41
52 Week High
$2.98
$9.99

Technical Indicators

Market Signals
Indicator
CDXS
SENS
Relative Strength Index (RSI) 47.97 74.02
Support Level $1.57 $5.13
Resistance Level $1.75 N/A
Average True Range (ATR) 0.10 0.54
MACD 0.04 0.11
Stochastic Oscillator 67.21 77.33

Price Performance

Historical Comparison
CDXS
SENS

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: